Argent Biopharma Seeks ASX Quotation for 1 Million New Shares

Argent Biopharma ( (AU:RGT) ) has issued an announcement.

Argent Biopharma Limited has applied for quotation of 1,000,000 ordinary fully paid shares on the Australian Securities Exchange under the code RGT. The newly quoted securities, issued on February 27, 2026, modestly expand the company’s listed share capital and may incrementally increase liquidity and broaden its shareholder base, though the announcement provides no additional detail on the purpose or terms of the issuance.

The move indicates ongoing capital markets activity by Argent Biopharma as it manages its funding and equity structure. For existing and prospective investors, the additional shares represent a small dilution but also a potential enhancement to trading depth and price discovery in the stock, depending on market demand for the new securities.

The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.

More about Argent Biopharma

Argent Biopharma Limited is an ASX-listed biotechnology company identified by issuer code RGT. The company operates in the biopharmaceutical sector, with its ordinary fully paid shares traded on the Australian Securities Exchange, giving investors access to its equity as it develops and commercialises its scientific and medical assets.

Average Trading Volume: 184,673

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$4.78M

For a thorough assessment of RGT stock, go to TipRanks’ Stock Analysis page.